--- title: Buy Farxiga (Dapagliflozin) 5mg, 10mg Pills Online description: Farxiga (Dapagliflozin) 5mg/10mg is a trusted treatment for type 2 diabetes and heart failure. Order now from our secure store for reliable delivery. type: product language: en url: https://medsforsale.net/buy-farxiga-online-en availability: in_stock price_min: 29.99 price_max: 91.99 currency: USD offers: - name: 5mg x 30 pills price: 29.99 - name: 5mg x 60 pills price: 41.99 - name: 5mg x 120 pills price: 53.99 - name: 5mg x 90 pills price: 53.99 - name: 5mg x 180 pills price: 57.99 - name: 10mg x 30 pills price: 35.99 - name: 10mg x 60 pills price: 53.99 - name: 10mg x 90 pills price: 68.99 - name: 10mg x 120 pills price: 83.99 - name: 10mg x 180 pills price: 91.99 --- # Buy Farxiga (Dapagliflozin) 5mg, 10mg Pills Online Farxiga, which contains the active ingredient Dapagliflozin, is an innovative SGLT2 inhibitor developed by AstraZeneca. It is primarily used to lower blood sugar levels in adults with type 2 diabetes and to reduce the risk of hospitalization for heart failure. This medication is for patients seeking effective glycemic control and cardiovascular protection. Our online pharmacy provides a secure platform to access Farxiga in 5mg and 10mg pills. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **5mg** | 30 pills | **$29.99** | $1.00 | In Stock | | **5mg** | 60 pills | **$41.99** | $0.70 | In Stock | | **5mg** | 120 pills | **$53.99** | $0.45 | In Stock | | **5mg** | 90 pills | **$53.99** | $0.60 | In Stock | | **5mg** | 180 pills | **$57.99** | $0.32 | In Stock | | **10mg** | 30 pills | **$35.99** | $1.20 | In Stock | | **10mg** | 60 pills | **$53.99** | $0.90 | In Stock | | **10mg** | 90 pills | **$68.99** | $0.77 | In Stock | | **10mg** | 120 pills | **$83.99** | $0.70 | In Stock | | **10mg** | 180 pills | **$91.99** | $0.51 | In Stock | [Buy Now](https://medsforsale.net/buy-farxiga-online-en) ## Introduction Farxiga (dapagliflozin) is an oral medication approved for the treatment of type 2 diabetes mellitus, chronic kidney disease (CKD), and heart failure with reduced ejection fraction (HFrEF). It belongs to the sodium-glucose cotransporter-2 (SGL 2) inhibitor class and is supplied as a film-coated tablet in 5 mg and 10 mg strengths. The drug is marketed worldwide by Astra Zeneca under the brand name Farxiga (United States) and as Forxiga in the European Union. In addition to its primary indications, clinicians occasionally consider dapagliflozin for off-label purposes such as type 1 diabetes or obesity-related metabolic improvement, always under specialist supervision. --- ## What is Farxiga? Farxiga is a branded SGL 2 inhibitor that contains the active pharmaceutical ingredient dapagliflozin. Developed by Astra Zeneca, the product received FDA approval in 2014 for glycemic control in adults with type 2 diabetes and has since gained additional approvals for CKD and HFrEF. The medication is formulated as a film-coated tablet intended for once-daily oral administration, with dose options of 5 mg and 10 mg. Farxiga is marketed under brand names such as Farxiga (U.S.) and Forxiga (EU). It is distinct from other SGL 2 inhibitors like canagliflozin (Invokana) and empagliflozin (Jardiance) but shares the same therapeutic class. --- ## How Farxiga Works Dapagliflozin blocks the sodium-glucose cotransporter-2 located in the proximal renal tubules. Under normal physiology, SGL 2 reabsorbs approximately 90 % of filtered glucose back into the bloodstream. Inhibition of this transporter reduces glucose reabsorption, causing excess glucose to be excreted in the urine (glycosuria). The resulting loss of glucose translates into lower plasma glucose levels and modest calorie loss, which helps improve glycemic control and can lead to weight reduction. Beyond glucose, the osmotic diuresis generated by glycosuria lowers intravascular volume, reduces blood pressure, and diminishes cardiac preload. These hemodynamic effects explain the cardiovascular and renal benefits observed in clinical trials. Dapagliflozin reaches peak plasma concentrations within 1-2 hours after ingestion and has a half-life of roughly 13 hours, supporting once-daily dosing. The drug is eliminated primarily unchanged in the urine, with minor hepatic metabolism. --- ## Conditions Treated with Farxiga - **Type 2 Diabetes Mellitus (T2DM).** By promoting urinary glucose excretion, dapagliflozin lowers HbA₁c by 0.5-1.0 percentage points when added to diet, exercise, or other antidiabetic agents. - **Chronic Kidney Disease (CKD).** In patients with an eGFR ≥ 25 mL/min/1.73 m², dapagliflozin slows the decline in renal function, reduces albuminuria, and lowers the risk of progression to end-stage kidney disease. - **Heart Failure with Reduced Ejection Fraction (HFrEF).** Clinical trials demonstrate a 26 % relative risk reduction in cardiovascular death or worsening heart failure hospitalizations, independent of diabetic status. The drug’s efficacy in these indications is supported by large, randomized, placebo-controlled studies such as DECLARE-TIMI 58 (T2DM), DAPA-CKD (CKD), and DAPA-HF (HFrEF). Regulatory agencies (FDA, EMA) have incorporated these outcomes into the approved labeling. --- ## Off-Label and Investigational Uses of Farxiga - **Type 1 Diabetes Mellitus.** Small phase-2 studies suggest that adjunctive dapagliflozin can lower insulin requirements and improve glycemic variability, but the risk of diabetic ketoacidosis (DKA) is higher. This application remains unapproved and should be undertaken only in specialized centers. - **Obesity and Metabolic Syndrome.** Preliminary investigations report modest weight loss (≈ 2-3 kg) and improved blood pressure when dapagliflozin is used without concurrent diabetes. Evidence is limited to short-term trials. - **Non-Alcoholic Fatty Liver Disease (NAFLD).** Early-stage clinical data indicate reductions in hepatic steatosis markers, though definitive outcome trials are pending. These uses are **not authorized by the FDA or EMA**. Patients interested in off-label therapy must discuss potential benefits and risks with a qualified healthcare professional who can monitor safety closely. --- ## Is Farxiga the Right Medication for You? Farxiga is appropriate for adults with: - Diagnosed type 2 diabetes who need additional glucose-lowering effect beyond metformin or other agents. - CKD stages 2-4 (eGFR ≥ 25 mL/min/1.73 m²) with albuminuria or progressive decline in renal function. - HFrEF with left ventricular ejection fraction ≤ 40 % (or ≤ 45 % in some regional labeling) who are already receiving standard heart-failure therapy. Contraindications include: - Type 1 diabetes or a history of DKA. - Severe renal impairment (eGFR < 25 mL/min/1.73 m²). - End-stage renal disease on dialysis. - Pregnancy, lactation, or planning to become pregnant. Clinicians typically avoid dapagliflozin in patients with recurrent urinary tract infections, active genital mycotic infections, or those taking strong CYP3A4 inhibitors that could raise plasma concentrations. --- ## Risks, Side Effects, and Interactions ### Common - Genital mycotic infection (e.g., vulvovaginal candidiasis, balanitis). - Urinary tract infection. - Increased urination (polyuria). - Mild hypotension, especially in the elderly or volume-depleted patients. ### Rare - Acute kidney injury, particularly when volume depletion occurs concurrently with diuretics or NSAIDs. - Severe hypoglycemia when combined with insulin or sulfonylureas; dose adjustments may be required. ### Serious - Diabetic ketoacidosis (DKA), including euglycemic DKA, which can develop with minimal hyperglycemia. - Fournier’s gangrene (necrotizing fasciitis of the perineum), an extremely rare but life-threatening infection. - Bone fractures (observed in some post-marketing reports). #### Drug-Drug Interactions - **Insulin / Sulfonylureas:** Potentiate hypoglycemia; consider dose reductions. - **Loop Diuretics:** Additive diuretic effect may increase risk of dehydration and hypotension. - **Rifampin:** Strong CYP3A4 inducer; may decrease dapagliflozin exposure, reducing efficacy. - **Ketogenic Diets:** Heighten risk of euglycemic DKA; caution is advised. #### Drug-Food Interactions - No specific food restrictions are required, but excessive alcohol consumption can precipitate dehydration and should be limited. Patients should remain hydrated, monitor blood glucose regularly, and seek medical attention for signs of infection, persistent dizziness, or unexplained nausea. --- ## Use: Dosing, Missed Dose, Overdose - **Standard Initiation:** 5 mg once daily taken in the morning with or without food. Dose may be increased to 10 mg based on clinical response and renal function. - **Renal Adjustment:** For eGFR 25-45 mL/min/1.73 m², maintain the 5 mg dose; avoid use when eGFR < 25. - **Missed Dose:** Take the forgotten tablet as soon as it is remembered on the same day. If it is already close to the time for the next dose, skip the missed tablet and resume the regular schedule. Do not double-dose. - **Overdose:** Symptoms may include excessive urination, dehydration, dizziness, or low blood pressure. In case of suspected overdose, seek emergency medical care; treatment is supportive, focusing on fluid replacement and monitoring renal function. **Practical Precautions** - Store tablets at 20-25 °C (68-77 °F) away from moisture and light. - Do not crush or chew; swallow whole. - Alcohol can amplify hypotensive effects; limit intake. - Operating heavy machinery is generally safe, but avoid tasks that require sustained concentration if you experience dizziness or low blood pressure. --- ## FAQ - **What should I do if I develop a genital yeast infection while taking Farxiga?** * Promptly treat the infection with an appropriate antifungal (e.g., topical azole). If infections recur, discuss alternative diabetes therapy with your clinician. - **Can I travel internationally with Farxiga tablets?** * Yes. Keep the medication in its original container, carry a copy of the prescription label, and be aware of the destination country's import regulations for prescription drugs. - **How does altitude affect the efficacy of dapagliflozin?** * Higher altitude can increase diuresis and may exacerbate dehydration. Maintain adequate fluid intake and monitor blood pressure more closely when staying at altitude for extended periods. - **Are there any differences between Farxiga tablets marketed in the U.S. and Europe?** * The active ingredient, dapagliflozin, is identical. Minor differences may exist in inactive excipients or tablet coating, which generally do not affect clinical performance. - **What is the appearance of a 10 mg Farxiga tablet?** * The 10 mg tablet is round, white, and bears the imprint “10 FARXIGA”. The 5 mg tablet is similarly shaped but imprinted “5 FARXIGA”. - **Will taking Farxiga affect a routine blood test for kidney function?** * Dapagliflozin can cause a modest, transient rise in serum creatinine shortly after initiation due to hemodynamic changes. This effect usually stabilizes, and clinicians interpret results in the context of therapy. - **Is it safe to use Farxiga together with a low-carb diet?** * Low-carb diets reduce circulating glucose, which may increase the relative risk of euglycemic DKA when combined with an SGL 2 inhibitor. Close monitoring of ketone levels is advisable. - **How long does it take for Farxiga to lower HbA₁c?** * Significant reductions in HbA₁c are typically observed after 12 weeks of consistent therapy, with maximal effect around 24 weeks. - **Can dapagliflozin be used in patients with a history of frequent urinary tract infections?** * Caution is recommended. Patients with recurrent UTIs should be evaluated for alternative agents or prophylactic strategies before initiating therapy. - **What storage conditions are required for Farxiga during hot summer months?** * Keep tablets in a cool, dry place below 30 °C (86 °F). If ambient temperatures exceed this, store the medication in a temperature-controlled cabinet or refrigerator (do not freeze). --- ## Glossary **SGL 2 Inhibitor** : A class of drugs that block the sodium-glucose cotransporter-2 in the kidneys, causing excess glucose to be excreted in the urine. **eGFR (estimated Glomerular Filtration Rate)** : A laboratory measurement that approximates kidney filtration capacity, expressed in mL/min/1.73 m². **Euglycemic DKA** : Diabetic ketoacidosis that occurs with normal or only mildly elevated blood glucose levels, a recognized risk when using SGL 2 inhibitors. **Albuminuria** : Presence of albumin in the urine, indicating kidney damage; often quantified as a urine albumin-to-creatinine ratio. --- ## Buying Farxiga from [our online pharmacy](https://medsforsale.net/buy-farxiga-online-en) Patients who encounter limited availability, high out-of-pocket costs, or privacy concerns can obtain Farxiga through **[our online pharmacy](https://medsforsale.net/buy-farxiga-online-en)**. By partnering with licensed overseas suppliers, we secure the medication at prices close to manufacturer cost, passing the savings directly to you. Each shipment is verified for authenticity, packaged discreetly, and dispatched with reliable tracking-typically 7 days for express service or 2-3 weeks for standard airmail. Our brokerage model ensures that only quality-controlled, fully regulated tablets reach your door, while maintaining strict confidentiality throughout the transaction. Whether you need a short-term supply or a long-term refill, the service is designed to provide a trustworthy, cost-effective path to access Farxiga when domestic channels are insufficient. --- ## Disclaimer The information presented about **Farxiga** is intended for general educational purposes and does not substitute for professional medical advice. Treatment decisions, including any off-label applications, must be made under the guidance of a qualified healthcare provider. Readers are assumed to be competent adults capable of evaluating health information responsibly. **[our online pharmacy](https://medsforsale.net/buy-farxiga-online-en)** supplies Farxiga to individuals who may have restricted access through conventional pharmacies or insurance plans, offering a more affordable generic alternative. Always consult a clinician before initiating, adjusting, or stopping any medication.